tiprankstipranks
Trending News
More News >
Ramsay Generale de Sante (FR:GDS)
:GDS

Ramsay Generale de Sante (GDS) AI Stock Analysis

Compare
1 Followers

Top Page

FR

Ramsay Generale de Sante

(LSE:GDS)

Rating:61Neutral
Price Target:
€11.50
▲(4.07%Upside)
The overall stock score reflects a mixed financial performance, with strengths in cash flow but significant profitability challenges and high leverage. Technical indicators suggest positive momentum, while valuation is constrained by a negative P/E ratio and lack of dividend yield.

Ramsay Generale de Sante (GDS) vs. iShares MSCI France ETF (EWQ)

Ramsay Generale de Sante Business Overview & Revenue Model

Company DescriptionRamsay Générale de Santé (GDS) is a leading private healthcare provider in France, operating a network of hospitals and clinics. The company offers a comprehensive range of medical services, including acute care, surgery, maternity care, oncology treatment, and rehabilitation. With a focus on delivering high-quality healthcare services, Ramsay Générale de Santé aims to meet the needs of patients across various medical specializations through its extensive network of healthcare facilities.
How the Company Makes MoneyRamsay Générale de Santé generates revenue primarily through patient services provided at its network of hospitals and clinics. The company earns money by billing for medical procedures, inpatient and outpatient care, and additional healthcare services such as diagnostic tests and consultations. Revenue streams are driven by reimbursements from public and private health insurance systems, as well as direct payments from patients. Additionally, strategic partnerships with healthcare professionals and collaborations with insurance providers and public health entities enhance its service offerings and contribute to its earnings.

Ramsay Generale de Sante Financial Statement Overview

Summary
Ramsay Generale de Sante shows a mixed financial picture. While revenue growth is positive, profitability has been impacted, leading to a negative net income. The balance sheet highlights high leverage, which could pose risks in managing liabilities. Cash flow generation remains a strength, providing some stability despite profit challenges. The company needs to address profitability issues to improve its overall financial health.
Income Statement
62
Positive
The income statement shows mixed performance. Revenue has grown steadily from $4.02B in 2021 to $5.14B TTM, with a recent growth rate of 2.74% compared to the previous annual period. However, net income has turned negative in the TTM period, indicating profitability challenges. EBIT and EBITDA margins have declined, reflecting operational inefficiencies or increased costs.
Balance Sheet
55
Neutral
The balance sheet reveals high leverage with a debt-to-equity ratio of 3.48 in the TTM period, indicating significant reliance on borrowed funds. Stockholders' equity has decreased, and the equity ratio stands at 17.37%, suggesting limited equity buffer against liabilities. The return on equity has turned negative due to the net loss, highlighting concerns about current profitability.
Cash Flow
68
Positive
Cash flow analysis shows some strengths, with positive free cash flow of $440M in TTM and a 5.19% growth from the previous period. The operating cash flow to net income ratio is robust due to strong cash flow generation despite a net loss. However, the free cash flow to net income ratio highlights the pressure on profitability.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue5.14B5.01B4.70B4.30B4.02B3.75B
Gross Profit1.41B3.94B3.72B3.41B3.20B3.01B
EBITDA535.50M591.30M656.30M691.00M604.00M543.80M
Net Income-79.70M-53.90M49.40M118.40M65.00M18.70M
Balance Sheet
Total Assets6.49B6.90B6.96B6.79B6.68B6.71B
Cash, Cash Equivalents and Short-Term Investments157.80M381.30M362.90M143.50M620.00M548.20M
Total Debt3.92B4.06B4.15B3.97B3.85B3.92B
Total Liabilities5.33B5.67B5.68B5.55B5.58B5.68B
Stockholders Equity1.13B1.19B1.25B1.21B1.07B1.01B
Cash Flow
Free Cash Flow440.00M418.30M426.70M68.90M475.90M560.90M
Operating Cash Flow607.50M586.80M598.90M262.50M652.30M729.60M
Investing Cash Flow-164.20M-180.50M-175.40M-471.10M-181.40M-186.20M
Financing Cash Flow-470.30M-401.50M-197.10M-264.20M-390.60M-377.20M

Ramsay Generale de Sante Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.05
Price Trends
50DMA
10.52
Positive
100DMA
10.27
Positive
200DMA
11.16
Negative
Market Momentum
MACD
0.11
Positive
RSI
58.45
Neutral
STOCH
45.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Positive. The current price of 11.05 is above the 20-day moving average (MA) of 11.04, above the 50-day MA of 10.52, and below the 200-day MA of 11.16, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 58.45 is Neutral, neither overbought nor oversold. The STOCH value of 45.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GDS.

Ramsay Generale de Sante Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€2.78B19.1314.95%0.44%12.07%20.48%
76
Outperform
€884.60M15.0310.64%1.19%1.88%5.79%
FRLNA
74
Outperform
€271.97M12.237.12%29.89%9.58%-6.69%
66
Neutral
€1.86B-0.83%4.64%57.96%
FRGDS
61
Neutral
€1.21B-6.74%5.79%-575.58%
55
Neutral
€4.60B16.80-50.16%3.64%15.33%-9.51%
47
Neutral
€1.84B0.02-22.82%8.43%-102.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:GDS
Ramsay Generale de Sante
11.00
-4.80
-30.38%
FR:VIRP
Virbac SA
342.00
-6.43
-1.84%
FR:VETO
VETOQUINOL
75.00
-19.07
-20.28%
FR:CLARI
Clariane
5.23
3.41
187.68%
FR:LNA
LNA Sante SA
25.80
1.42
5.84%
FR:EMEIS
Orpea SA
11.48
-0.32
-2.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025